Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, August 03, 2016
Sekisui XenoTech has added additional hepatotoxicity screening assays and methodologies to the company’s existing cytotoxicity contract research services. Cytotoxicity studies assess the risk that test articles may cause toxicity in cells, with ...
read more
Wednesday, August 16, 2017
Sekisui XenoTech announced the addition of the H0606.S9(AX) Pooled Human Liver S9 and H0606.C(AX) Pooled Human Liver Cytosol test systems to the company’s catalog of in vitro drug development products.
read more
Thursday, October 19, 2017
Sekisui XenoTech announced the appointment of Dr. Darren Warren, PhD, as the company’s new Chief Operating Officer.
read more
Sekisui XenoTech now offers human liver tissue microarrays and a microsomal pool for studying and developing new treatments for fatty liver disease.
read more
SEKISUI XenoTech will celebrate its 25th anniversary this November, coming into the year with record-breaking achievements.
read more
Sekisui Diagnostics Enzyme business announces the completion of a new BioProcess Innovation Centre at the site in Maidstone, Kent by the end of 2019, following a $1.9 million investment.
read more
Seegene announced Health Canada authorized the import and sale in of Allplex™ 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2.
read more
Monday, December 28, 2015
Seattle Genetics, Inc. and Bristol-Myers Squibb have announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with CD30-expressing relapsed or ...
read more
Tuesday, December 08, 2020
SeaCube recently acquired 200 Carrier Pods monitored by Sensitech to help address the anticipated increase in demand for refrigerated storage capacity for COVID-19 vaccine distribution.
read more
Monday, December 08, 2025
SeaBeLife has signed a joint development agreement with Unither Pharmaceuticals for the production of clinical and commercial batches of the topical ophthalmic formulation of the SBL03 drug candidate. SBL03 is intended to treat degenerative disorders...
read more
SDC, a specialized data services Contract Research Organization (CRO) providing scalable clinical trial solutions, has opened a new office in Waltham, Mass. Fueled by accelerated growth and continued high demand for its services, SDC’s strategic ...
read more
Thursday, November 08, 2012
SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the ...
read more
SCYNEXIS, Inc. announced today that Merck, known as MSD outside the United States and Canada, has decided to return to SCYNEXIS all development and commercialization rights for the novel antifungal compound, MK-3118, an oral glucan synthase inhibitor...
read more
Thursday, February 18, 2021
SCYNEXIS has entered into a licensing agreement and strategic partnership with Hansoh Pharmaceutical Group.
read more
SCYNEXIS, Inc. announced today that Immune Design Corp. has selected SCYNEXIS as its chemical development and cGMP production partner for manufacture of Glucopyranosyl Lipid A (GLA).
read more